Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Director · Chief Scientific Officer | January 03, 2022 | January 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date January 03, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.39 · Expires 2032-01-02 | Direct | 125,000 |
Reported balance
After 2022-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-03 · Grant · Acquired 125,000 · Balance 125,000 F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 5, 2022 21:53 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001209191-22-001754 · doc4.xml · derivative · entry 1 Dominy Stephen S. · CIK 0001770860 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant. Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 23:47 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 763 | $14.40 | $10,987.20 |
DisclosureSEC source: 0001209191-21-064346 · doc4.xml · nonDerivative · entry 1 Dominy Stephen S. · CIK 0001770860 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Dominy Family Trust 2016 Disclosed balance after: 1,217,086 F1 · ownership.nature: Stephen S. Dominy is a trustee of the Dominy Family Trust 2016, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Dominy Family Trust 2016. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 00:07 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-063602 · doc4.xml · derivative · entry 2 Dominy Stephen S. · CIK 0001770860 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-10 F2 · derivative.exercise_date: 50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share. Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 00:07 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-063602 · doc4.xml · derivative · entry 1 Dominy Stephen S. · CIK 0001770860 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 23:12 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $54.85 | $0.00 |
DisclosureSEC source: 0001209191-20-008068 · doc4.xml · derivative · entry 1 Dominy Stephen S. · CIK 0001770860 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.